Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386455 | 0.87 | TDP1 (0.61) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL6815895 | 0.81 | — | — | |
| SCHEMBL11440963 | 0.79 | ALDH1A1 (0.49) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL11838471 | 0.78 | TDP1 (0.48) | TDP1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL8370815 | 0.77 | TDP1 (0.52) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL4303054 | 0.77 | TDP1 (0.42) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL4306587 | 0.76 | TDP1 (0.61) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL27598058 | 0.74 | TDP1 (0.39) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL7788656 | 0.74 | TDP1 (0.80) | TDP1ALDH1A1CTSBMEN1KMT2A | |
| SCHEMBL4049852 | 0.72 | PDE10A (0.56) | TDP1ALDH1A1CTSBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105936659-B | Mono- ligand metallic catalysts of stereochemical structure N, N and preparation method thereof | 宜春学院 | 2018-01-30 | — | — | CN | claimed |
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | claimed |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-05-28 | — | — | US | claimed |
| CN-102504056-B | N,O-double ligand metal catalyst with stereo structure and preparation method | UNIV NANCHANG | 2014-07-16 | — | — | CN | claimed |
| CN-102399323-B | N,O-single ligand metal catalyst with stereochemical structure and preparation method thereof | UNIV NANCHANG | 2014-05-14 | — | — | CN | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | claimed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | claimed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | claimed |
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | THE UNIVERSITY OF MONTANA (US) | 2007-06-21 | — | — | US | claimed |
| EP-0839807-A1 | Synthesis of benzo(f)quinolinones | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0476456-B1 | Substituted 2-thiazolyl tetrazolium salt indicators | BAYER AG (US) | 1997-11-12 | — | — | EP | claimed |
| EP-0476454-B1 | Analytical method using tetrazolium salt indicators having a reflectance plateau | BAYER AG (US) | 1996-10-23 | — | — | EP | claimed |
| US-5290536-A | Phenyl substituted 2-thiazolyl tetrazolium salt indicators | MILES INC. (US) | 1994-03-01 | — | — | US | claimed |
| US-5126275-A | Chromogenic reducing indicators for reducing substances such as NADH | MILES INC. (US) | 1992-06-30 | — | — | US | claimed |
| EP-0476455-A2 | Phenyl-substituted 2-thiazolyl tetrazolium salt indicators | Bayer Corporation (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0476454-A1 | Analytical method using tetrazolium salt indicators having a reflectance plateau | Bayer Corporation (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0476457-A2 | 2-Benzothiazolyl tetrazolium salt indicators | Bayer Corporation (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0476456-A2 | Substituted 2-thiazolyl tetrazolium salt indicators | Bayer Corporation (US) | 1992-03-25 | — | — | EP | claimed |
| US-4224071-A | Black dyes for ball-point pen inks | AMERICAN CYANAMID COMPANY (US) | 1980-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142467-A1 | 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission | SLC1A1, SLC1A3, SLC1A2 | TDP1 1968/4885ALDH1A1 929/4885CTSB 3893/4885 |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | TDP1 777/4885ALDH1A1 671/4885CTSB 743/4885 |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | CACNB2, CACNB1, CACNB4 | TDP1 4801/4885ALDH1A1 4200/4885CTSB 1602/4885 |
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | TDP1 4624/4885ALDH1A1 2490/4885CTSB 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.